1. Home
  2. ABLV vs EQ Comparison

ABLV vs EQ Comparison

Compare ABLV & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABLV
  • EQ
  • Stock Information
  • Founded
  • ABLV 2015
  • EQ 2017
  • Country
  • ABLV China
  • EQ United States
  • Employees
  • ABLV N/A
  • EQ N/A
  • Industry
  • ABLV
  • EQ Biotechnology: Pharmaceutical Preparations
  • Sector
  • ABLV
  • EQ Health Care
  • Exchange
  • ABLV Nasdaq
  • EQ Nasdaq
  • Market Cap
  • ABLV 38.1M
  • EQ 39.0M
  • IPO Year
  • ABLV N/A
  • EQ 2018
  • Fundamental
  • Price
  • ABLV $0.88
  • EQ $0.69
  • Analyst Decision
  • ABLV
  • EQ Buy
  • Analyst Count
  • ABLV 0
  • EQ 2
  • Target Price
  • ABLV N/A
  • EQ $5.00
  • AVG Volume (30 Days)
  • ABLV 12.9K
  • EQ 311.2K
  • Earning Date
  • ABLV 01-01-0001
  • EQ 11-13-2024
  • Dividend Yield
  • ABLV N/A
  • EQ N/A
  • EPS Growth
  • ABLV 18.07
  • EQ N/A
  • EPS
  • ABLV 0.24
  • EQ N/A
  • Revenue
  • ABLV $148,999,819.00
  • EQ $42,623,000.00
  • Revenue This Year
  • ABLV N/A
  • EQ N/A
  • Revenue Next Year
  • ABLV N/A
  • EQ N/A
  • P/E Ratio
  • ABLV $3.66
  • EQ N/A
  • Revenue Growth
  • ABLV 2.58
  • EQ 26.25
  • 52 Week Low
  • ABLV $0.67
  • EQ $0.48
  • 52 Week High
  • ABLV $3.94
  • EQ $3.25
  • Technical
  • Relative Strength Index (RSI)
  • ABLV 42.79
  • EQ 41.51
  • Support Level
  • ABLV $0.82
  • EQ $0.68
  • Resistance Level
  • ABLV $0.94
  • EQ $0.89
  • Average True Range (ATR)
  • ABLV 0.05
  • EQ 0.11
  • MACD
  • ABLV 0.00
  • EQ -0.03
  • Stochastic Oscillator
  • ABLV 35.67
  • EQ 12.17

About ABLV Able View Global Inc.

Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.

About EQ Equillium Inc.

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Share on Social Networks: